295 related articles for article (PubMed ID: 23621902)
1. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH
BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
Chhatwal J; Ferrante SA; Brass C; El Khoury AC; Burroughs M; Bacon B; Esteban-Mur R; Elbasha EH
Value Health; 2013; 16(6):973-86. PubMed ID: 24041347
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Blázquez-Pérez A; San Miguel R; Mar J
Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
9. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
[TBL] [Abstract][Full Text] [Related]
14. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Manns MP; McCone J; Davis MN; Rossaro L; Schiff E; Shiffman ML; Bacon B; Bourliere M; Sulkowski MS; Bruno S; Balart L; Bronowicki JP; Kwo P; Poordad F; Felizarta F; Reddy KR; Helmond FA; Sings HL; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Vierling JM
Liver Int; 2014 May; 34(5):707-19. PubMed ID: 24118703
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir for untreated chronic HCV genotype 1 infection.
Poordad F; McCone J; Bacon BR; Bruno S; Manns MP; Sulkowski MS; Jacobson IM; Reddy KR; Goodman ZD; Boparai N; DiNubile MJ; Sniukiene V; Brass CA; Albrecht JK; Bronowicki JP;
N Engl J Med; 2011 Mar; 364(13):1195-206. PubMed ID: 21449783
[TBL] [Abstract][Full Text] [Related]
17. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir for previously treated chronic HCV genotype 1 infection.
Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Goodman ZD; Sings HL; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R;
N Engl J Med; 2011 Mar; 364(13):1207-17. PubMed ID: 21449784
[TBL] [Abstract][Full Text] [Related]
19. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
Vellopoulou A; van Agthoven M; van der Kolk A; de Knegt RJ; Berdeaux G; Cure S; Bianic F; Lamotte M
Appl Health Econ Health Policy; 2014 Dec; 12(6):647-59. PubMed ID: 25103219
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
